TClC effectively suppresses the growth and metastasis of NSCLC via polypharmacology

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) remains a significant global health challenge with poor survival rates, often due to treatment resistance and metastasis.
• Existing therapies like targeted treatments and immunotherapies have limitations in overcoming drug resistance and metastatic progression in NSCLC.

Purpose of the Study:

• To synthesize and evaluate a novel bioactive compound, ethyl 6-chlorocoumarin-3-carboxylyl L-theanine (TClC), for its efficacy against NSCLC.
• To investigate TClC's mechanism of action, particularly its effects on cancer stem cells and drug resistance pathways.

Main Methods:

• Synthesis of the novel compound TClC.
• In vitro and in vivo studies to assess TClC's impact on NSCLC growth, epithelial mesenchymal transition (EMT), migration, invasion, and metastasis.
• Molecular assays to identify direct binding targets of TClC.

Main Results:

• TClC significantly inhibited NSCLC growth, EMT, migration, and invasion in vitro, and reduced tumor growth and metastasis in vivo without observed toxicity.
• TClC disrupted autocrine loops in CD133-positive NSCLC cells, crucial for metastasis.
• Direct molecular targets of TClC were identified as Akt, NF-κB, β-catenin, EZH2, and PD-L1, leading to suppression of oncogenic factors and multidrug resistance.

Conclusions:

• TClC demonstrates significant anti-cancer activity against NSCLC, including resistant and metastatic forms.
• The compound's polypharmacological action, targeting multiple critical cancer pathways, makes it a promising therapeutic candidate.
• TClC represents a potential new era for NSCLC treatment development by targeting key drivers of tumor progression and resistance.